Point72 Hong Kong’s Kite Pharma, Inc. KITE Stock Holding History

Point72 Hong Kong’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7	Closed	-$1K	–	1157
2017 Q1	$1K	Buy	+7	New	+$433	﹤0.01%	708

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Point72 Hong Kong's KITE Position: Q2 2017 in Review

Point72 Hong Kong sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 7 shares — an estimated $1K sold.

Point72 Hong Kong first reported a position in KITE in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

Point72 Hong Kong reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
Point72 Hong Kong sold 7 Kite Pharma, Inc. shares in Q2 2017, an estimated $1K.
Point72 Hong Kong first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 1 quarter.
Point72 Hong Kong's Kite Pharma, Inc. position peaked at $1K in Q1 2017.
220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Point72 Hong Kong's 13F filing for Q2 2017, filed 14 Aug 2017.